Horizons

Opinion & insight from our Clinical Steering Group

Horizons, led by a team of experts from our Clinical Steering Group, is a series of scientific articles which take a deep dive into the emerging trends in the healthcare landscape, kickstarting a dialogue about how novel treatments and strategies could change prospects for patients in the near future.

We're discussing new treatments, strategies and devices, and how they are set to disrupt healthcare practices in the coming years. Some of the topics we'll be tackling include:

  • Moderate-to-severe psoriasis

  • Antibody-drug conjugates

  • Immuno-oncology

  • Cardiology devices

  • Oral proteasome inhibitors in multiple myeloma

  • PARP inhibitors

  • Alzheimer's disease

  • CAR-T therapies in oncology

What's on the Horizon?

Dr Cornelia Meisenberg

Moderate-to-severe psoriasis: the disease burden and unmet needs in different patient groups

Posted 9 days ago

Welcome to part one of this three-part series comparing treatments for moderate-to-severe psoriasis. In this first part, we will discuss the unmet need and burden of disease in distinct patient groups, the pathophysiology of the disease and the treatment options currently available.

In the subsequent parts, we will discuss:

Part 2: Treating moderate-to-severe psoriasis in young women of childbearing age

Part 3: Considering differences in the evidence base for moderate-to-severe psoriasis treatments

Throughout the series, we present key opinions from Professor Diamant Thaçi, the director of the Comprehensive Center of Inflammation Medicine at the University of Lübeck, Germany. Professor Thaçi’s work over the last 30 years includes both basic and clinical drug development studies for multiple chronic inflammatory skin disorders, including psoriasis.

Marshall Pearce

How close are we to a disease-modifying treatment for Alzheimer’s?

Posted 2 years ago

Alzheimer’s disease is a snowballing problem, one that is currently without a convincing solution. The progressive decline in cognitive function seen in patients with Alzheimer’s disease is associated strongly with plaques formed of amyloid beta in the brain, creating neurofibrillary tangles and leading to neuronal destruction. While some treatments improve cognition in the short-term, current therapeutic options are unable to modify or slow the disease process.

Penny Staton

Improving non-alcoholic steatohepatitis care – is the finishing line in sight?

Posted 2 years ago

An intense race is going on right now in non-alcoholic steatohepatitis (NASH) research. A number of significant players within the pharmaceutical and biotechnology sectors are competing to develop the first major therapeutic advance in treatment for this neglected condition. But should we consider it more of a relay race? Could improved diagnosis, disease assessment and even combination therapy be the key to victory over this increasingly prevalent disease?

Marshall Pearce

Left ventricular assist devices – A viable therapeutic option for heart failure?

Posted 2 years ago

Alongside a pharmacological strategy to aid myocardial recovery, LVADs may prove to have a significant role to play in the ever-growing problem of heart failure. Although LVADs are not new onto the scene, the advance of technology – smaller, more efficient devices with better reliability and potentially transcutaneous power transfer – means we may be on the cusp of seeing many more deployed to tackle heart failure.

Marshall Pearce

Cancer immunotherapies

Posted 2 years ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 2 years ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Related learning zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Biosimilars Knowledge Centre

Biosimilars Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more